EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Avanos Medical Inc (AVNS) fair value: what the stock is really worth

As of Jul 24, 2026: fair value of Avanos Medical Inc $8.95, price $24.99, upside -64.2%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US05350V1061

AM Avanos Medical Inc logo Some data Sep 24, 2026

Avanos Medical Inc

AVNS · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $8.95 · Strongly overvalued (−64.2%)
!Quality 58/100
!Weak Growth (revenue 5y −0.4 %/yr)
!Loss-making · -10.4% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (4/12)
!Narrow moat 27/100
!Evidence only medium, so the estimate is less certain
Watch Avanos Medical Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$45.46 $9.89 Fair Value $8.95 Apr 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $9.89 – $45.46 · fair‑value band $7.11 – $11.49 · the $24.99 price screens above the $8.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Avanos Medical in your weekly email

Every Wednesday you see whether Avanos Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

Show more

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Stock analysis

Avanos Medical Inc (AVNS) currently trades at $24.99, while our model-based Fair Value estimate is $8.95, 64.2% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $11.95 per share, and 0 of the 7 models we run sit above the $24.99 price.

Bear case: the DCF Models group reads lowest at $10.44, and 7 of the 7 models stay below the price. Evidence for this calculation is medium.

Scenario range: $7.11 (bear) to $11.49 (bull), the price of $24.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Avanos Medical Inc reported revenue of $701M in FY2025 versus $745M in FY2021, a compound −1.5%/yr. Reported net income was −$67.9M in FY2025.

Key figures

Market cap $1.2B · P/S ratio 1.63 · EPS (TTM) $−1.60 · Net margin −9.7% · Return on equity −9.2% · Return on assets (EBIT) 1.9% · Operating margin 5.4% · Revenue (TTM) $716M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 153% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −64%, AVNS screens richer than that median.

Fair Value models

Bear $7.11 Fair Value $8.95 Bull $11.49
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $8.00 $10.44 $14.52 81
Growth DCF $8.26 $10.57 $14.14 80
5Y Revenue Exit $7.82 $11.20 $16.11 73
All 7 models by family
DCF Models
FCF DCF $8.00 $10.44 $14.52 81
5Y Revenue Exit $7.82 $11.20 $16.11 73
10Y Revenue Exit $7.67 $10.02 $12.51 68
Multiples
EV/Revenue $8.36 $11.95 $15.54 53
Asset-Based
NCAV (Graham) $8.31 $11.13 $16.61 54
Growth DCF
Growth DCF $8.26 $10.57 $14.14 80
Rev-Margin DCF $7.82 $11.41 $15.84 73

Open the full fair value analysis →

Notify me when AVNS reaches fair value

Put AVNS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 56 · Market factors (momentum, volatility) 66

Profitability 21
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 68
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 9
Calm price path (market factor)
Momentum 84
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Start year 2020 (pandemic). Over 10 years: −7.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.8% (2019) → −8.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +20.1% a year for the price.

AVNS screens overvalued: fair value 64% below the price. Compare with Abbott Laboratories, →

Compare Avanos Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −64.2% · Bottom 25%
Profitability
Return on assets 1.0% · Below median
Net margin (TTM) −10.4% · Below median
Operating margin (TTM) 5.4% · Below median
Growth and dividend
Revenue growth 8.8% · Above median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.49× · Cheaper than median
P/S (TTM) 1.62× · Cheaper than median
P/FCF 26.9× · Pricier than median
EV/EBITDA 20.8× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)44 · sector 31
PAST (return on equity)0 · sector 11
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Avanos Medical Inc · Fair Value
$8.95 −64%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Avanos Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVNS

Frequently asked questions

Is Avanos Medical Inc (AVNS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $8.95 versus the last price from Jul 24, 2026 of $24.99, about −64% upside (overvalued).
What is the fair value of AVNS?
Our model-based fair value for Avanos Medical Inc is $8.95 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 24, 2026): $24.99.
What is the quality score of AVNS?
Avanos Medical Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avanos Medical Inc (AVNS)?
Our model-based price target is the fair value of $8.95 (as of Sep 24, 2026) from 7 valuation models. Cautious scenario $7.11, optimistic scenario $11.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Avanos Medical Inc stock forecast for 2026?
Our models put fair value at $8.95, about −64% upside versus the last price from Jul 24, 2026 of $24.99 (overvalued). Cautious scenario $7.11, optimistic scenario $11.49. The calculation is refreshed regularly with new filings.
What is the revenue of Avanos Medical Inc (AVNS)?
Avanos Medical Inc reported trailing-twelve-month revenue of about $716M (latest available figure, as of Sep 24, 2026).
What growth is priced into Avanos Medical Inc (AVNS)?
For today's price to be fair in a discounted-cash-flow model, Avanos Medical Inc would have to grow free cash flow by +23.0 % per year for five years (discount rate 12.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of AVNS use?
Our models discount Avanos Medical Inc at 12.8 %: a base by market capitalisation (small), damped by beta 1.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Avanos Medical Inc that is +23.0 % per year a year over ten years, using the same discount rate (12.8 %) and the same formula as our fair value.
How much growth has Avanos Medical Inc (AVNS) delivered so far?
Over the past 5 years revenue at Avanos Medical Inc grew -0.4 % a year. The price currently implies +23.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Avanos Medical Inc (AVNS) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Avanos Medical Inc (+23.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Avanos Medical Inc (AVNS)?
The free-cash-flow yield on the price is 3.72 %: that much free cash flow Avanos Medical Inc produces per unit of market value. When it exceeds the discount rate of our models (12.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Avanos Medical Inc (AVNS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avanos Medical Inc it is $8.95 per share (as of Sep 24, 2026), against a price of $24.99. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Avanos Medical Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AVNS trades above its calculated fair value: price $24.99, fair value $8.95, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVNS?
No. The price is what the market pays today ($24.99); the fair value is what the company's own numbers justify ($8.95). For Avanos Medical Inc the two are $16.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avanos Medical Inc worth?
The market values Avanos Medical Inc at about $1.2B (market capitalisation, as of Sep 24, 2026). Per share that is $24.99; our models calculate a fair value of $8.95 per share.
What do the bullish and bearish scenarios say about AVNS?
Our models span a range for Avanos Medical Inc: cautious scenario $7.11, base $8.95, optimistic $11.49 per share (as of Sep 24, 2026, price $24.99). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Avanos Medical Inc (AVNS)?
Balance-sheet figures for Avanos Medical Inc (as of Sep 24, 2026): return on equity −9.2%, debt of 0.12 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is AVNS from its 52-week high?
Avanos Medical Inc trades at $24.99, at its 52-week high of $25.05 and 153% above the low of $9.89 (as of Jul 24, 2026). Distance from the high says nothing about value: that is what the fair value of $8.95 is for.
Which stocks are comparable to Avanos Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avanos Medical Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $24.99, calculated fair value $8.95 (−64%), Quality Score 58/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVNS calculated?
We run Avanos Medical Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.95, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Avanos Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avanos Medical Inc (AVNS)?
The latest price we hold is from Jul 24, 2026 and stands at $24.99. Our model-based fair value is $8.95, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avanos Medical Inc right now?
The price sits above even our optimistic bull case ($11.49). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Avanos Medical Inc

How large is the market capitalisation of Avanos Medical Inc (AVNS)?
The market capitalisation of Avanos Medical Inc is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avanos Medical Inc (AVNS)?
The price-to-sales ratio of Avanos Medical Inc is 1.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Avanos Medical Inc (AVNS)?
Earnings per share at Avanos Medical Inc are $−1.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Avanos Medical Inc (AVNS)?
The net margin of Avanos Medical Inc is −9.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Avanos Medical Inc (AVNS)?
The return on equity (ROE) of Avanos Medical Inc is −9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avanos Medical Inc (AVNS)?
On an EBIT basis the return on assets of Avanos Medical Inc is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avanos Medical Inc (AVNS)?
The operating margin of Avanos Medical Inc is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Avanos Medical Inc (AVNS)?
Revenue at Avanos Medical Inc is growing +8.8% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Avanos Medical Inc (AVNS)?
Earnings per share at Avanos Medical Inc are growing −21.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Avanos Medical Inc (AVNS) carry?
The net debt of Avanos Medical Inc is $39.3M (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Avanos Medical Inc in the live analysis

One click puts Avanos Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.